Ovarian cancer remains one of the deadliest gynecological cancers worldwide, primarily due to its frequent late-stage diagnosis and subtle early symptoms. Among the various histological types, HGSOC is notoriously aggressive and often resistant to conventional therapies. Understanding the genetic underpinnings of this malignancy is crucial as it can inform personalized treatment strategies and improve survival outcomes. The current study embarks on dissecting the prevalence and nature of mutational changes in a North African population that has been historically underrepresented in genomic cancer research.

Targeted next-generation sequencing was employed to examine 31 cancer-associated genes in 54 Tunisian patients diagnosed with HGSOC. Both germline DNA, obtained from blood samples, and somatic DNA from formalin-fixed paraffin-embedded (FFPE) tumor tissues were analyzed. This dual approach enabled the team to distinguish inherited mutations from those acquired during tumor development, providing a nuanced understanding of the tumor biology specific to this ethnicity and environment.

The findings revealed that 20.3% of the patients harbored pathogenic germline variants (PVs), whereas somatic PVs were present in 27.77% of the cohort. Strikingly, five individuals exhibited pathogenic variants in the BRCA1 gene at both the germline and somatic level, indicating a complex interplay that could influence tumor progression and therapeutic responses. The BRCA genes, especially BRCA1 and BRCA2, are well-known tumor suppressors involved in DNA repair mechanisms, and their disruption is linked with hereditary breast and ovarian cancers.

Beyond BRCA genes, somatic mutations were identified in crucial homologous recombination (HR) repair pathway genes, including ATM, RAD50, and BRIP1. These genes play pivotal roles in maintaining genomic integrity by orchestrating the repair of double-strand DNA breaks. Their alteration suggests that defects in DNA repair pathways are central to the pathogenesis of Tunisian HGSOC, potentially rendering patients amenable to treatments exploiting these vulnerabilities, such as PARP inhibitors.

One of the study’s notable discoveries was the identification of four recurrent BRCA1 pathogenic variants, among which a novel mutation was documented. This finding not only enriches the global catalog of BRCA mutations but also hints at a possible founder effect or unique mutational spectrum in the Tunisian population. Such insights are crucial for developing population-specific genetic screening panels that can facilitate early detection and preventive strategies.

Age also emerged as a significant factor, with germline BRCA1/2 pathogenic variants predominantly found in patients younger than 50 years old. This demographic correlation underscores the importance of genetic counseling and testing, particularly in younger ovarian cancer patients, to enable timely interventions and inform at-risk family members. Moreover, carriers of these germline mutations demonstrated better overall survival, suggesting that the presence of BRCA mutations may confer therapeutic sensitivity, likely due to the tumor’s defective DNA repair mechanisms.

In addition to pathogenic mutations, the research uncovered 19 variants of uncertain significance (VUS), highlighting the complexities of interpreting NGS data. The classification and clinical relevance of these VUS remain ambiguous, underscoring the need for further functional studies and integrative bioinformatics approaches to elucidate their potential role in cancer biology.

This pioneering study provides a valuable reference point for oncologists and geneticists working with North African populations. It emphasizes that genetic diversity and population-specific mutational profiles can profoundly impact disease behavior and response to therapy. Consequently, the study advocates for the integration of comprehensive genetic testing into routine clinical management of ovarian cancer, particularly in genetically distinct populations.

Importantly, the discovery of key mutations in genes involved in the homologous recombination repair pathway paves the way for precision oncology. Patients harboring such alterations might benefit from emerging targeted therapies, including PARP inhibitors, which exploit tumor-specific weaknesses in DNA repair. Personalized treatment regimens based on genetic profiling can potentially improve prognosis and quality of life for affected women.

The research also carries significant implications for genetic counseling. Identification of germline mutations mandates family risk assessment and could lead to preventive interventions such as prophylactic surgeries or enhanced surveillance. This is especially relevant in populations where inherited cancer susceptibility genes may exhibit unique mutational patterns.

Importantly, the study calls attention to the role of ethnic and geographic factors in shaping the mutational landscape of ovarian cancer. Tunisia’s distinct genetic background underscores the need for expanding genomic studies beyond commonly studied Western populations to achieve more equitable and effective cancer care worldwide.

Taken together, the study provides robust evidence that somatic and germline mutations in key cancer-associated genes are common among Tunisian women with HGSOC. This genomic insight advances our understanding of tumor biology and offers new directions for personalized therapy and genetic counseling tailored to this specific demographic.

The study’s comprehensive mutation profiling exemplifies how next-generation sequencing can unravel the complex genetic architecture of aggressive cancers, fostering the development of targeted treatment options and enhanced patient stratification. As precision medicine continues to evolve, such population-specific investigations will be instrumental in closing existing disparities in cancer outcomes globally.

Future research building upon these findings is necessary to delineate the functional impacts of identified variants and to translate genetic discoveries into clinical practice. Collaborative efforts between clinicians, geneticists, and researchers will be critical to harness the full potential of genomic medicine in managing ovarian cancer and improving patient survival rates.

Subject of Research: Genetic profiling of germline and somatic mutational variants in Tunisian high-grade serous ovarian carcinoma patients.

Article Title: Germline and somatic mutational variants of Tunisian high grade serous ovarian cancer identified by next-generation sequencing.

Article References:
Ammous-Boukhris, N., Abdelmaksoud-Dammak, R., Ben Kridis, W. et al. Germline and somatic mutational variants of Tunisian high grade serous ovarian cancer identified by next-generation sequencing. BMC Cancer 25, 1542 (2025). https://doi.org/10.1186/s12885-025-14989-x

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-14989-x

HER2, also known as ERBB2, is a well-established oncogene implicated in a variety of malignancies, most notably breast and gastric cancers. However, its role in lung cancer—particularly NSCLC—has emerged more recently, revealing a niche yet vital subset of patients whose tumors harbor activating mutations or amplifications of this gene. The current investigation focuses on a cohort of 13 patients from Northeastern Brazil with identified HER2 mutations in NSCLC tumors, drawing attention not only to the presence of these mutations but also to their extensive genomic interplay with other oncogenic drivers. This nuanced molecular profiling propels the study beyond mere identification, providing a window into the intricate mutational landscapes that drive tumor behavior in this demographic.

The cohort ranged widely in age from 34 to 82 years, with a slight female predominance and nearly half classified as non-smokers—a noteworthy epidemiological feature given the traditionally strong association of lung cancer with tobacco exposure. Morphologically, the tumors exhibited classic adenocarcinoma patterns, with histopathological examination detailing mixed acinar and papillary architectures. Notably, immunohistochemical analysis revealed low-level HER2 protein expression despite DNA-level mutations, a finding underscored by dual in situ hybridization techniques confirming the absence of gene amplification. These subtleties emphasize the complexity inherent in relying solely on protein expression or amplification status to define HER2 involvement in NSCLC.

Genomic interrogation uncovered a rich tapestry of co-occurring mutations. Alterations in TP53, KRAS, and STK11 genes frequently accompanied HER2 mutations, underscoring the multifaceted oncogenic networks that coalesce within these tumors. Among the HER2 mutations identified, exon 20 insertions predominated, conforming to a hotspot region known to induce constitutive activation of the HER2 tyrosine kinase domain. This mechanistic detail furthers our understanding of how these mutations contribute to malignant transformation and progression in NSCLC, offering tangible targets for pharmacologic intervention.

From a therapeutic standpoint, the study paints a sobering picture of current clinical realities. Despite the availability of promising HER2-targeted agents, notably trastuzumab deruxtecan (T-DXd)—the first FDA-approved drug to demonstrate robust efficacy in HER2-mutant NSCLC—the majority of patients in this cohort did not receive targeted therapy. Instead, conventional modalities such as surgery, chemotherapy, and immunotherapy were predominantly employed, reflecting both access barriers and the necessity for heightened awareness and infrastructure to implement molecular testing and precision medicine strategies in low-resource settings.

The disparity in treatment outcomes was stark. Survival times ranged widely, with some individuals achieving protracted remission extending several years post-diagnosis, while others succumbed rapidly, within months. This heterogeneity not only mirrors the underlying biological complexity revealed by the molecular data but also highlights the critical importance of early, accurate diagnosis paired with the optimal therapeutic approach. The authors rightly advocate for integrating comprehensive molecular profiling into routine diagnostic algorithms, advocating a tiered strategy that begins with baseline screening for actionable mutations followed by more sophisticated genomic analyses when warranted.

Importantly, this study addresses a significant gap in cancer research by spotlighting a population that has been historically marginalized in genomic and clinical oncology research. Latin America, and particularly regions like Northeastern Brazil, are underrepresented in large-scale cancer genomics initiatives. This lack of representation constrains global understanding of disease biology and impedes equitable drug development and clinical guideline formulation. By elucidating the unique molecular features and clinical patterns of NSCLC with HER2 mutations in this geographic and ethnic context, the research elevates the imperative for inclusive, region-specific cancer research endeavors.

The study’s findings also provoke reflection on the molecular diagnostic tools currently available and their performance in diverse populations. The relatively low HER2 protein expression despite the presence of activating mutations invites reconsideration of reliance on immunohistochemistry (IHC) alone for patient selection in clinical trials and therapeutic decision-making. Dual in situ hybridization assays and next-generation sequencing (NGS) emerge as indispensable adjuncts to uncover the full spectrum of HER2 alterations and accompanying mutations, thereby refining patient stratification and enhancing personalized medicine.

Moreover, the research team’s proposal of a tiered diagnostic framework tailored to resource availability and clinical need represents a pragmatic model with potential applicability far beyond the study’s geographic confines. Starting with cost-effective screening methods and escalating to detailed genomic profiling as indicated, such an approach could democratize access to precision oncology and improve clinical outcomes through appropriate therapeutic sequencing.

This research further underscores the transformative potential of novel HER2-directed therapies like trastuzumab deruxtecan, which have demonstrated significant response rates and progression-free survival benefits in HER2-mutant NSCLC. However, the limited use of these agents within the studied cohort delineates pressing access issues. Addressing these gaps necessitates concerted efforts to build infrastructure, training, and healthcare policies that promote molecular testing and equitable distribution of targeted treatments, especially in low- and middle-income countries.

Future directions prompted by this work include expanding cohort sizes to validate findings and unravel prognostic implications of different HER2 mutation subtypes. Additionally, longitudinal studies integrating clinical outcomes with molecular profiles will be crucial to ascertain predictive biomarkers of treatment response and resistance mechanisms. Ultimately, these endeavors will inform guidelines that are both globally relevant and locally adaptable.

In addition to clinical and molecular insights, the study carries socio-ethical ramifications, emphasizing the need for global oncology communities to prioritize underrepresented populations to achieve health equity. The research thus serves as a clarion call to dismantle barriers that have historically limited access to cutting-edge cancer diagnostics and therapeutics worldwide.

In conclusion, this seminal investigation charts critical molecular and clinical terrain by decoding the complex landscape of HER2-mutated NSCLC in Northeastern Brazil. By highlighting the intricate genomic interplay, diagnostic hurdles, treatment disparities, and the pressing need for expanded molecular profiling and targeted therapy access, it propels the field toward more inclusive, precise, and effective lung cancer management strategies. The study not only enriches scientific understanding but also reinforces the broader imperative of global health equity in oncology research and care.

Article Title: Molecular landscape of HER2-mutated non-small cell lung cancer in Northeastern Brazil: Clinical, histopathological, and genomic insights

News Publication Date: 17-Jun-2025

Web References:

• Oncotarget Volume 16: https://www.oncotarget.com/archive/v16/
• DOI: 10.18632/oncotarget.28737

Image Credits: Copyright: © 2025 Nogueira et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0).

Keywords: cancer, HER2 mutation, NSCLC, lung cancer, targeted therapy, genomic profiling